Skip to content

Preferred Stock at other companies

Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
$0
Allogene Therapeutics logo
Allogene TherapeuticsALLO
$0
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
$0
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$0
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$0
Janux Therapeutics logo
Janux TherapeuticsJANX
$0

Other financials

Income statement

See full
Operating income-$41.4M+12.7%
Net income-$39.7M+11.0%
EPS (diluted)-$0.66+35.9%

Balance sheet

See full
Cash & equivalents$32.2M-43.4%
Total debt$9.2M+32.1%
Total equity$195.6M-12.7%
Total assets$257.0M-1.4%

Cash flow

See full
Operating cash flow-$41.6M+7.4%
CapEx$2.0K-98.0%
Free cash flow-$33.5M+10.8%

Valuation

See full
Market cap$498.52M+276%
Enterprise value$475.49M+475%

Returns & leverage

See full
Return on equity-74.5%+74.4pp
Debt / equity0.0×
Current ratio8.1×+0.7×

Where this comes from

Reported directly by Kyverna Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockValue.

The official record: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kyverna Therapeutics, Inc.'s preferred stock.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kyverna Therapeutics, Inc.'s preferred stock?
Kyverna Therapeutics, Inc. (KYTX) reported preferred stock of $0 in Q1 2026.
What does preferred stock mean?
Equity securities with priority over common stock for dividends and liquidation proceeds, but typically without voting rights.